Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Judith Rubinstein"'
Publikováno v:
International Journal of Technology Assessment in Health Care. 37:38-38
IntroductionPatient access schemes (PAS) are agreements that may enable patients to access drugs or other treatments that may not be cost effective under normal circumstances. The aim of this study was to determine whether the use of PAS by the Natio
Publikováno v:
International Journal of Technology Assessment in Health Care. 37:38-38
IntroductionThe National Institute of Health and Care Excellence (NICE) issued a supplementary advice in 2009 stating that treatments for patients with short life expectancies (MethodsHealth technology assessments (HTAs) conducted by NICE from 2009 t
Publikováno v:
International Journal of Technology Assessment in Health Care. 35:84-85
IntroductionEuropean agencies evaluate the adverse events (AEs) of asthma drugs in studies. The impact of these evaluations on reimbursement decisions remains unclear.MethodsAdult asthma evaluations were accessed from initial regulatory decision by t
Autor:
Emily Rubinstein, B.F. Lurie, Anson Pontynen, S. Yin Ho, Boaz Adler, Ashley Jaksa, Jake Blumenthal, Judith Rubinstein, Rachel Sliman, Ruth Chang
Publikováno v:
International Journal of Technology Assessment in Health Care. 33:220-221
INTRODUCTION:Immunotherapies are a relatively new innovative class of drug that have garnered excitement in the fight against cancer. In 2011, the immunotherapy drug, ipilimumab, was approved. Since then, four additional drugs have gained approval. T
Publikováno v:
International Journal of Technology Assessment in Health Care. 33:2-3
INTRODUCTION:As of July 2016, funding from England's Cancer Drugs Fund (CDF) is dispensed based on the results of National Institute for Health and Care Excellence (NICE) technology appraisal guidances instead of independent CDF appraisals (1). As pa
Publikováno v:
International Journal of Technology Assessment in Health Care. 33:145-146
INTRODUCTION:New immunotherapies have had great successes, but also incredibly debilitating side effects for patients. This discrepancy needs to be a focus of pharmaceutical companies because it will affect the way Health Technology Assessment (HTA)
Publikováno v:
International Journal of Technology Assessment in Health Care. 33:156-156
INTRODUCTION:As of July 2016, funding from England's Cancer Drugs Fund (CDF) is dispensed based on the results of National Institute for Health and Care Excellence (NICE) technology appraisal guidances instead of independent CDF appraisals (1). NICE
Autor:
Judith Rubinstein
The UH-72A Light Utility Helicopter (LUH) was acquired for performance of general support tasks (training, medical evacuation, law enforcement, etc.) in permissive (noncombat) environments, to replace Vietnam-era helicopters, and to free up Black Haw
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8ca086a40ceb6e2b30ffc3edc509721d
https://doi.org/10.21236/ada620879
https://doi.org/10.21236/ada620879